In the present study, we describe the combined effect of EGF+61G>A and TGFB1+869T>C polymorphisms, according to genetic proliferation profiles that could influence disease outcomes, such as the progression-free interval and the overall survival of RCC patients. The gene discussed is TGFB1; the disease is renal cell carcinoma.